Hypocalcemia induced by raloxifene.

Area of Science:

• Endocrinology
• Pharmacology
• Bone Metabolism

Background:

• Raloxifene is a selective estrogen receptor modulator (SERM) used to treat and prevent osteoporosis in postmenopausal women.
• Osteoporosis management often involves anti-resorptive agents to reduce bone loss.
• Vitamin D deficiency is a common condition, particularly in older adults and those with limited sun exposure.

Observation:

• A case of clinically significant hypocalcemia was observed in a patient undergoing raloxifene treatment.
• The patient had undiagnosed, latent vitamin D deficiency.
• This adverse event highlights a potential drug-nutrient interaction.

Findings:

• Raloxifene therapy precipitated severe hypocalcemia in a patient with occult vitamin D deficiency.
• This suggests that raloxifene's anti-resorptive effects can unmask or exacerbate pre-existing vitamin D deficiency.
• The interaction underscores the importance of baseline vitamin D status.

Implications:

• Clinicians should consider screening for vitamin D deficiency before initiating raloxifene or other anti-resorptive therapies.
• Correction of vitamin D deficiency prior to treatment may prevent adverse events like hypocalcemia.
• This finding has implications for patient safety in osteoporosis management and public health regarding vitamin D screening.